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Dyslipidemia and the progression of renal disease in chronic
renal failure patients. Dyslipidemia is a common complication
of progressive kidney disease and contributes to the high car-
diovascular morbidity and mortality of chronic kidney disease
(CKD) patients. Recent evidence also suggests a role for dys-
lipidemia in the development and progression of renal disease.
Experimental studies have demonstrated that lipids may induce
glomerular and tubulointerstitial injury, and that lipid-lowering
treatments ameliorate renal injury.
Various lipid abnormalities have been associated with the
development and progression of renal disease in diabetic and
nondiabetic patients. Population-based studies and studies of
diabetic patients have reported associations of various lipid ab-
normalities with the development of renal disease. In patients
with CKD, lipid abnormalities have also been associated with
renal disease progression. Post hoc analyses of some large clin-
ical trials on patients with vascular disease, diabetes, or dys-
lipidemia, and a meta-analysis of small, prospective, controlled
studies on patients with CKD (diabetics and nondiabetics) sug-
gest that statins may slow the progression of kidney disease.
It is unclear whether the beneficial renal effects of statins are
due to the reduction of serum cholesterol levels and/or their
pleiotropic effects. There is also evidence for synergistic reno-
protective effects between statins and renin-angiotensin system
inhibitors. According to the results of post hoc analysis of sev-
eral studies, treatment with fibrates does not seem to confer
renoprotection, but evidence is scarce.
In summary, there is growing evidence that lipid abnormali-
ties may be a risk factor for renal disease, and that statins appear
to confer a renoprotective effect.
Dyslipidemia is a common complication of progressive
kidney disease, which is characterized by high triglyceride
and low high-density lipoprotein (HDL) cholesterol lev-
els, accumulation of remnant particles, a predominance
of small dense low-density lipoprotein (LDL) particles,
and increased levels of lipoprotein A. In patients with
advanced chronic kidney disease (CKD), LDL and HDL
particles undergo oxidative modification, resulting in the
formation of small lipoproteins and enhanced produc-
tion of oxidized LDL [1]. In the nephrotic syndrome, the
lipid profile is highly atherogenic, with increased total and
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LDL cholesterol, triglyceride, and lipoprotein A serum
levels as well as decreased HDL cholesterol.
Dyslipidemia has been hypothesized to cause kid-
ney damage and to play an important role in the pro-
gression of renal failure [2]. In animal models, hyper-
lipidemic diets worsen renal injury, and lipid-lowering
strategies ameliorate renal injury [3–6]. Dyslipidemia
may damage glomerular capillary endothelial and mesan-
gial cells as well as podocytes. Mesangial cells express
receptors for LDL and oxidized LDL, which upon ac-
tivation induce mesangial cell proliferation, increase
mesangial matrix deposition, and enhance the pro-
duction of chemokines (such as macrophage chemo-
attractant protein-1), cytokines (such as interleukin 6), or
growth factors. Macrophage chemo-attractant protein-1
enhances the recruitment of macrophages, which can in-
filtrate the glomerulus and become foam cells that re-
lease cytokines. Oxidized LDL increases the adhesion
of monocytes to glomerular endothelial cells, favoring
monocyte infiltration, and affects tubular epithelial cells
[6]. Hypercholesterolemia and hypertriglyceridemia are
also associated with podocyte injury, which secondarily
leads to mesangial sclerosis [4]. Oxidized LDL induces
apoptosis of podocytes and nephrin loss (a key compo-
nent of the glomerular filtration barrier), and increases
albumin diffusion in podocyte monolayers in vitro [7].
The evidence for dyslipidemia as an independent risk
factor for renal disease development and/or progression
is not as strong in clinical human studies as it is in experi-
mental studies. Existing evidence for the involvement of
dyslipidemia in the development and/or progression of
CKD and the possible beneficial effects of lipid-lowering
therapy on renal disease progression in humans are re-
viewed in this article.
DYSLIPIDEMIA AND DEVELOPMENT OF
CHRONIC KIDNEY DISEASE
Several studies have shown that dyslipidemia may
be a risk factor for renal disease. In the Atheroscle-
rosis Risk in Communities study, high triglyceride and
low HDL cholesterol levels were associated with an
S-87
S-88 Cases and Coll: Dyslipidemia and renal disease
increased risk for developing renal dysfunction [8]. Data
from the Physicians’ Health Study indicated that ele-
vated total cholesterol levels, high non-HDL cholesterol
levels, and LDL/HDL cholesterol ratios, as well as low
HDL cholesterol levels were all associated with an in-
creased risk of serum creatinine elevation (serum creati-
nine >1.5 mg/dL) during follow-up in apparently healthy
men with normal renal function at baseline [9]. Low HDL
cholesterol levels were also an independent risk factor for
the development of incident CKD (glomerular filtration
rate [GFR] <60 mL/min per 1.73 m2) in the Framingham
Offspring study [10]. In middle-aged dyslipidemic men
included in the Helsinki Heart Study, lower HDL and
higher LDL/HDL cholesterol ratios were associated with
a faster decline in GFR over time in hypertensive patients
[11]. In an observational study of 1428 hospital-based,
ambulatory patients with an estimated GFR >70 mL/min
that were followed up for 5 to 6 years, patients with serum
cholesterol >350 mg/dL during the follow-up period were
more likely to have a decline in renal function than pa-
tients with a maximum cholesterol level<250 mg/dL. This
observation occurred both in diabetics (relative risk 2.4,
95% confidence interval 1.1–5.2) and in nondiabetics (rel-
ative risk 4.0, 95% confidence interval 1.3–12.5) [12]. In
a retrospective study on essential hypertensive patients
with normal GFR at baseline who were followed up for
more than 13 years, baseline systolic blood pressure and
mean total cholesterol levels were significant risk fac-
tors for developing renal failure (GFR <60 mL/min per
1.73 m2) [13].
A prospective study evaluated 574 patients with type 2
diabetes mellitus of recent onset with normal renal func-
tion and urinary albumin excretion rate at baseline who
were followed up for a mean of 7.8 years. In the multi-
ple regression analysis, mean blood pressure and levels
of total cholesterol and hemoglobin A1c were the main
factors associated with a decrease in renal function and
with an increase in albuminuria. HDL was also associated
with the degree of albuminuria and duration to develop-
ment of microalbuminuria [14]. In 176 patients with type
2 diabetes and normoalbuminuria, the 5-year cumulative
incidence of microalbuminuria was 23%. Risk factors
for the development of incipient or overt nephropathy
were increased urinary albumin excretion rate, male sex,
age, presence of retinopathy, and increased serum choles-
terol and hemoglobin A1c concentrations [15]. Among
420 type 1 diabetic patients, the 10-year incidence of
overt nephropathy was 12%. The adjusted relative risk
for overt nephropathy associated with triglycerides in
the range of 150 to 199 mg/dL was 3.2, and 3.0 for val-
ues ≥200 mg/dL, compared with baseline triglycerides
<100 mg/dL [16]. Similar results were observed in a co-
hort of 297 type 1 diabetic patients without end-stage
renal disease who were followed up for 7 years. Serum
triglyceride levels were higher in patients who progressed
in nephropathy than in those who did not, both in the
whole cohort and in patients with normoalbuminuria at
baseline, even after adjustment for systolic blood pres-
sure, diabetes duration, gender, stage of complications at
baseline, and hemoglobin A1c [17]. In another study, the
10-year incidence of renal insufficiency in 634 type 1 di-
abetic patients was associated with age, hemoglobin A1c,
hypertension, and serum HDL cholesterol levels after
adjusting for the presence of microalbuminuria or albu-
minuria at baseline [18]. Conversely, the World Health
Organization Multinational Study of Vascular Disease in
Diabetes, which included 959 type 1 and 3558 type 2 dia-
betic patients with a mean follow-up of 8.4 years, failed to
show an association of serum cholesterol with develop-
ment of renal failure. Serum triglycerides were associated
with appearance of renal failure only in type 2 diabetic
patients [19]. Other studies have found no association
between serum lipid levels and nephropathy in type 1 or
type 2 diabetic patients [20–22] (See Table 1).
DYSLIPIDEMIA AND CKD PROGRESSION
In the Modification of Diet in Renal Disease study,
which included patients with moderate-to-severe renal
disease of various etiologies, low HDL independently
predicted a faster decline in GFR [23]. In a prospective
study in 73 nondiabetic patients with primary CKD, to-
tal cholesterol, LDL cholesterol, and apolipoprotein B
were all significantly associated with a rapid decline in re-
nal function, whereas triglycerides, HDL cholesterol, and
apolipoprotein A were not [24]. In another prospective
study that assessed the risk of CKD progression to dial-
ysis in a cohort of 138 patients followed up for 12 years,
hypertriglyceridemia was of borderline significance for
progression to dialysis in the multivariate analysis [25].
Among 104 patients with CKD who were followed up
for a mean of 4.1 years, total cholesterol and urinary pro-
tein scores were positively related to the progression of
renal disease [26]. However, in the Northern Italian Co-
operative Study Group trial, plasma lipid levels did not
significantly affect the renal outcome in a cohort of 456
patients with CKD [27]. Similarly, a small study failed
to show differences in lipid parameters between patients
whose renal disease progressed and those whose renal
disease did not [28].
In the Early Treatment Diabetic Retinopathy Study,
which included 2226 diabetic patients (934 type 1 and
1292 type 2) with retinopathy, the 5-year estimated in-
cidence of renal replacement therapy (RRT) (defined
as the need for dialysis or transplantation) was 10.2%
and 9.8% for patients with type 1 and type 2 diabetes,
respectively. Baseline risk factors for RRT common to
type 1 and type 2 diabetes included elevated total choles-
terol, serum creatinine, low serum albumin levels, and
anemia. In type 2 diabetes, but not in type 1 diabetes,
Cases and Coll: Dyslipidemia and renal disease S-89
Table 1. Development and/or progression of kidney disease and plasma lipids
Study Patients Number Follow-up D/P Lipid
ARIC study [8] Population-based 12728 2.9 yr D ↑TG, ↓HDL
Physician’s Health Study [9] Healthy men 4483 14 yr D ↑TCh, ↑non-HDL,
↑LDL/HDL, ↓HDL
Framingham Offspring Study [10] Population-based 2585 18.5 yr D ↓HDL
Helsinki Heart Study [11] Dyslipidemic men 2702 5 yr D ↑LDL/HDL and ↓HDL
(Only hypertensives)
Hsu CY et al [12] Hospital-based ambulatory 1428 5.7 yr D ↑TCh
population
Segura J et al [13] Hypertensive (retrospective) 281 13.2 yr D ↑TCh
Ravid M et al [14] T2DM 574 7.8 yr D ↑TCh
MAB and ↓ HDL
Gall MA et al [15] T2DM 176 5.8 yr D ↑TCh
Orchard TJ et al [16] T1DM 420 10 yr D/P ↑TG
Hadjadj S et al [17] T1DM 297 7 yr D/P ↑TG
Klein R et al [18] T1DM 634 10 yr D/P Decline GFR and ↑TCh
Incidence RI ↓ HDL
Watts GF et al [70] T1DM 53 10 yr D Increase albuminuria ↑TCh, LDL, ApoB
WHO MSVDD [19] T1DM 3558 8.4 yr D ↑TG in DM-type 2
T2DM 959/2559 No association TCh
EURODIAB [20] T1DM 250 7.4 yr D No association TCh or TG
Wirta OR et al [21] T2DM 109 5.8 yr D/P No association TCh
Oue T et al [22] T2DM 67 10 yr D/P No association TCh, HDL, TG
MDRD Study [23] CRF 840 2.2 yr P ↓HDL
Samuelsson O et al [24] CRF non-DM 73 3.2 yr P ↑TCh, ↑ LDL, ↑Apo B
Massy ZA et al [25] CRF 138 12 yr P ↑TG, ↓HDL (univariate)
Washio M et al [26] CRF 104 4.1 yr P ↑TCh
Locatelli F et al [27] CRF 456 2 yr P No relationship
Cappelli P et al [28] CRF 52 1 yr P No relationship
Ravid M et al [30] T2DM with MAB 94 5 yr P ↑TCh
Solini A et al [31] T2DM with MAB 65 4 yr P ↑TCh and HindIII polymorphism of LPL
Yokoyama H et al [32] T2DM and nephropathy 182 P ↑TCh
Smulders YM et al [33] T2DM with MAB 58 24 m P ↑TG, ↓HDL
Nielsen S et al [34] T2DM normo or MAB 32 5.5 yr P No association
Krolewski AS et al [35] T1DM and 439 8 yr P ↑TCh
Nephropathy
EURODIAB [36] T1DM with MAB 352 7 yr P ↑ TG (univariate)
Mulec H et al [37] T1DM and nephropathy 30 2.5 yr P ↑TCh, ↑TG, ↑Apo B
ETDRS study [29] DM and retinopathy T1 934 6.5 yr P T1DM ↑ TCh
T2 1232 5.9 yr T2DM ↑ TCh and TG
Abbreviations are: D, development; P, progression; ARIC, Atherosclerosis Risk In Communities (study); yr, years; TG, triglycerides; HDL, high-density lipoprotein;
TCh, total cholesterol; LDL, low-density lipoprotein; LDL/HDL, ratio LDL/HDL; T2DM, type 1 diabetes mellitus, MAB, microalbuminuria; T2DM, type 2 diabetes
mellitus; GFR, glomerular filtration rate; RI, renal insufficiency; Apo B, apolipoprotein B; CRF, chronic renal failure; LPL, lipoprotein lipase; m, months.
elevated triglycerides were also a risk factor for RRT
[29]. In other studies of type 2 diabetic patients, base-
line levels of serum cholesterol predicted the progression
of nephropathy [30–32]. In another study, serum triglyc-
eride and HDL cholesterol levels were associated with
progression [33], but another study found no association
between renal disease progression and lipid levels in this
subset of patients [34]. In type 1 diabetic patients, both
serum cholesterol and triglyceride levels have been asso-
ciated with progression of nephropathy in some studies
[35–37] (see Table 1).
The independent association between hypercholes-
terolemia and/or hypertriglyceridemia and elevated uri-
nary albumin excretion rate in nondiabetic populations
is also controversial and inconsistent. Both negative and
positive results have been reported, and there is no agree-
ment on the lipid fraction involved [38–42].
These studies indicate an association between hyper-
lipidemia and renal disease development and/or progres-
sion, suggesting that hyperlipidemia is a risk factor for
renal disease, although no definitive conclusions can be
drawn. It is also not clear whether dyslipidemia increases
the renal risk in those without other risk factors for kid-
ney disease, because most studies that have evaluated the
effects of dyslipidemia on renal disease have been per-
formed with patients with pre-existing renal disease or
other risk factors for renal disease, such as hypertension
and diabetes. The risk of loss of renal function associ-
ated with dyslipidemia seems to be highest in those with
moderate-to-severe renal disease and other renal risk fac-
tors, such as hypertension and diabetes. Another aspect
that remains unanswered is which lipoprotein or lipopro-
teins better predict renal disease development and/or
progression, because the data are inconsistent regarding
the ability of cholesterol (or its fractions) and/or triglyc-
erides to predict the progression of renal disease [43].
Finally, in some of these studies, the possible role of un-
measured confounders, such as the metabolic syndrome,
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cannot be ruled out. In fact, the metabolic syndrome,
which is associated with high triglyceride and low HDL
cholesterol levels, has been recently associated with the
development of CKD during follow-up in the Atheroscle-
rosis Risk in Communities study [44].
RENAL DISEASE PROGRESSION AND
LIPID-LOWERING TREATMENT
Although no large, randomized, controlled trials have
evaluated the effect of treating hyperlipidemia on the
progression of kidney disease, there is an increasing
amount of evidence that lipid-lowering agents, particu-
larly statins, may have a renoprotective effect. A post
hoc subgroup analysis of the Cholesterol And Recurrent
Events study, in a randomized trial of pravastatin ver-
sus placebo in patients with a history of myocardial in-
farction, demonstrated that treatment with the statin was
associated with a reduced rate of renal function loss in
patients with moderate-to-severe renal failure, especially
in those with proteinuria [45]. The MRC/BHF Heart
Protection Study was a randomized, placebo-controlled
trial that evaluated the effects of lowering serum choles-
terol with simvastatin in patients with previous cardio-
vascular disease or diabetes (5903 diabetic patients and
14,573 nondiabetic patients). Allocation to simvastatin
(40 mg/day) was associated with a smaller increase in
serum creatinine during a mean follow-up of 4.6 years,
both in diabetic and nondiabetic patients. This protec-
tive effect was slightly greater in diabetic patients [46].
In the Greek Atorvastatin and Heart Disease Evalua-
tion study, 1600 patients with established coronary heart
disease were randomized to atorvastatin or placebo. A
post hoc analysis demonstrated that, over the 36 months
of follow-up, patients allocated to atorvastatin showed a
12.2% increase in creatinine clearance (CrCl) compared
with a 5.2% decrease in statin-free patients; similar re-
sults were observed in the subgroup of diabetic patients
[47]. Conversely, in a substudy of the Lescol Interven-
tion Prevention Study, which assessed the effect of flu-
vastatin (80 mg/day) on major adverse cardiac events
after a first successful transcatheter therapy in patients
with renal dysfunction (N = 310) and those without it
(N = 1248), renal function remained stable throughout
the follow-up. The predicted clearance-time profile was
not influenced by fluvastatin therapy, regardless of base-
line CrCl [48]. In a pooled analysis of data from more than
10,000 hyperlipidemic patients included in the clinical-
development program of rosuvastatin, mean GFR was
higher when compared with baseline both early and later
in the course of rosuvastatin treatment (5–40 mg/day);
no change in GFR was observed in the placebo group.
Among patients who received long-term rosuvastatin
treatment (≥96 weeks), GFR was unchanged or tended
to increase, rather than decrease, which suggests that this
drug slows the progression of renal disease [49].
A recent meta-analysis of 13 small controlled trials on
patients (N = 384) with CKD, more than half of whom
had diabetes, suggested that lipid-lowering agents, most
of which were statins, were renoprotective, as shown by a
significantly lower rate of decline in GFR and a reduction
in urinary protein excretion [50]. In this meta-analysis,
longer follow-up correlated with the amount of improve-
ment in GFR from treatment. However, there was high
heterogeneity between the trials, which may be due to
the small number of trials, sample size, differences in the
etiology of renal disease, duration of treatment, type and
dose of statin, severity of albuminuria at baseline, and
methodologic differences in GFR and albuminuria mea-
surements. Thus, these data should be interpreted with
caution. In hypertensive dyslipidemic patients with mild
renal dysfunction, treatment with pravastatin was also
associated with a decline in renal function (assessed by
serum creatinine) that was slower than that of a match-
ing group given a placebo [51]. In a 1-year prospective,
placebo-controlled, open-label study on patients with
CKD, proteinuria, and hypercholesterolemia, patients re-
ceiving atorvastatin had a small, non-significant decline
in CrCl, whereas those receiving placebo showed a sig-
nificant decrease in renal function [52].
There is also evidence of a synergistic effect between
statins and renin-angiotensin system inhibitors on renal
protection. In the previously mentioned study, patients
had already been treated with an angiotensin-converting
enzyme inhibitor or an angiotensin receptor blocker, and
allocation to atorvastatin was associated with stabiliza-
tion of renal function at 1 year compared with a decrease
in CrCl in the untreated group [52]. Furthermore, in this
and other studies, statins added to angiotensin-converting
enzyme inhibitors or angiotensin receptor blocker re-
sulted in further reduction of proteinuria [52–54].
Statins have also been reported to reduce albuminuria
in patients with nephrotic syndrome [55] and chronic
glomerulonephritis [54, 56], in normolipidemic, well-
controlled hypertensive patients [53] and in normoten-
sive and hypertensive type 2 diabetic patients [57–61]
in most studies, although negative results have been re-
ported in some studies of type 1 and type 2 diabetic pa-
tients [62–64]. Conversely, the Prevention of Renal and
Vascular End-stage Disease Intervention Trial failed to
show a beneficial cardiovascular or renal effect (reduc-
tion in microalbuminuria) of pravastatin in 854 partici-
pants with microalbuminuria after 4 years of treatment
[65].
Taken together, these studies suggest that treatment
with statins may reduce the rate of progression of re-
nal damage in patients with coronary heart disease or
other cardiovascular diseases, in patients with diabetes
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Table 2. Effect of lipid-lowering drugs on renal disease progression
Study Drug Patients Number Follow-up Results
CARE study [45] Pravastatin MI 4159 58,9 m ↓Renal loss
(CRF) (690)
MRC/BHF HPS study [46] Simvastatin CVD or DM 5903 DM 4,6 yr ↓ Increase in sCr in DM & non-DM
14572 non-DM
GREACE study [47] Atorvastatin CHD 1600 3 yr ↑GFR
LIPS study [48] Simvastatin CAD and PCA 1558 3–4 yr No difference in GFR vs. PLA
(CRF) (310)
Vidt DG et al [49] Rosuvastatin Hyperlipidemic 10.000 Up to 3.8 yr GFR tendency ↑
Fried LF et al [50] Mainly statins Meta-analysis 384 Preserved GFR
Imai Y et al [51] Pravastatin Hypertensive CKD 57 6 m No ↑ sCr with treatment
Bianchi S et al [52] Atorvastatin CKD treated with 56 1 yr Preserved GFR
RAS inhibitors
Buemi M et al [56] Fluvastatin IgA nephropathy 21 6 m No  GFR but ↓ UAE
Lam KS et al [71] Lovastatin DM-type 2 34 2 yr Lower ↓ GFR
VA-HIT [69] Gemfibrozil CHD 2532 61 m None
(CRF) 399
DAIS [68] Fenofibrate DM-type 2 + CHD 312 38 m ↓ Appearance/progression UAE
Helsinki Heart Study [11] Gemfibrozil Dyslipidemic 2702 5 yr None
Abbreviations are: CARE, Cholesterol Amd Recurrent Events (study); MI, myocardial infarction; CRF, chronic renal failure; m, months; HPS, Heart Protection
Study; CVD, cardiovascular disease; DM, diabetes mellitus; yr, years; sCr, serum creatinine; GREACE, Greek Atorvastatin and Heart Disease Evaluation (study);
CHD, coronary heart disease; GFR, glomerular filtration rate; LIPS, Lescol Intervention Prevention Study; CAD, coronary artery disease; PCA, percutaneous coronary
angioplasty; PLA, placebo; RAS, renin-angiotensin system; IgA, immunoglobulin A; , variation; UAE, urinary albumin excretion; VA-HIT, Veterans Affairs High
Density Lipoprotein trial; DAIS, Diabetes Atherosclerosis Intervention Study.
and hyperlipidemia, or in those with CKD. Although the
possible renoprotective mechanisms of statins may be
due to the LDL lowering effect, data suggest that they
may be related to their pleiotropic effects. In fact, in a
randomized, crossover study that compared the effects
of simvastatin and cholestyramine in 26 microalbumin-
uric type 2 diabetic patients, despite a similar reduction
in plasma lipids, only simvastatin reduced urinary albu-
min excretion rate [58]. Statins prevent the development
of glomerular scarring in obese Zucker rats and Dahl salt-
sensitive rats. Statins also inhibit the proliferation of sev-
eral cell lines (mesangial cells, renal, tubular, or vascular
smooth muscle cells) and induce apoptosis. Statins inhibit
the release of chemokines and cytokines by mesangial
cells and monocytes. They also inhibit the production of
matrix components, such as collagen or fibronectin, by
mesangial cells. In addition, statins improve endothelial
function, which may have potentially beneficial hemody-
namic renal effects [66]. In patients with polycystic kid-
ney disease, simvastatin treatment for 4 weeks produced
a 6.5% and 25% greater increase in GFR and effective re-
nal plasma flow, respectively, compared with placebo [67].
Statins also inhibit oxidized LDL-induced apoptosis, loss
of nephrin in glomerular podocytes, and increased albu-
min diffusion in podocyte monolayers, thus providing a
rationale for the antiproteinuric effect of statins [67].
Statins appear to have important potential in the treat-
ment of progressive renal disease, although further stud-
ies with humans are required to confirm this. The Study
of Heart and Renal Protection (SHARP) may help to
elucidate this issue. SHARP is a large-scale, random-
ized, placebo-controlled trial designed to evaluate the ef-
fects of cholesterol-lowering treatment with simvastatin
(20 mg/day) plus ezetimibe (10 mg/day) on major car-
diovascular events in patients with CKD without known
cardiovascular disease. This study will include 9000 pa-
tients: 6000 with CKD (serum creatinine ≥1.5 mg/dL in
women and ≥1.7 mg/dL in men) and 3000 on dialysis. The
primary outcome will be the time to a first cardiovascu-
lar event, defined as a composite of myocardial infarc-
tion, cardiac death, stroke, or coronary or noncoronary
revascularization. Progression of renal disease will be a
secondary outcome of the study.
The possible beneficial effect of fibrates on renal func-
tion has been evaluated in a few studies, and the results
are inconsistent. In the Helsinki Heart study, no benefi-
cial effect of gemfibrozil on renal function during follow-
up was observed in male hyperlipidemic patients [11].
In contrast, in a post hoc analysis of data from the Dia-
betes Atherosclerosis Intervention Study on patients with
type 2 diabetes mellitus and coronary heart disease, this
randomized trial of fenofibrate versus placebo showed
that the progression to microalbuminuria was reduced in
the fenofibrate group after 38 months of follow-up [68].
Conversely, in a post hoc analysis of the Veterans Affairs
High Density Lipoprotein trial on patients with coro-
nary heart disease and HDL cholesterol complex level
≤40 mg/dL, LDL cholesterol complex ≥140 mg/dL, and
triglycerides ≤300 mg/dL who were randomized to gem-
fibrozil or placebo, 399 patients had moderate chronic re-
nal failure. Gemfibrozil did not significantly modify the
rate of change in renal function in these patients com-
pared with the placebo group after a median follow-
up of 61.4 months. Furthermore, active treatment did
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not significantly affect the likelihood of developing re-
nal failure in patients with baseline GFR ≥60 mL/min
per 1.73 m2 [69]. Thus, there is no evidence for a nephro-
protective effect of treatment with fibrates (see Table 2).
CONCLUSION
There is increasing evidence for an association of dys-
lipidemia and the occurrence and progression of renal
disease in both diabetic and nondiabetic patients. Treat-
ment with statins seems to ameliorate the progression of
renal disease, although it is unclear whether this is due
to the lowering of LDL cholesterol or to the pleiotropic
effects of statins. However, these findings require confir-
mation by large, prospective, randomized trials such as
the SHARP trial.
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